Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Hydronidone Capsules in Healthy Chinese Subjects
NCT04162821Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydronidone in Liver Fibrosis (LF) and Chronic Hepatitis B (CHB) (3 arms), sponsored by Gyre Pharmaceuticals. Primary endpoint: Plasma drug concentration up to 12 weeks. Started Oct 2019; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04162821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162821.